Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001628280-20-010607
Filing Date
2020-07-24
Accepted
2020-07-24 17:16:36
Documents
16
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A cpix-20200331.htm   iXBRL 10-Q/A 95662
2 EX-31.3 a2020q1-exhibit31310qa.htm EX-31.3 6941
3 EX-31.4 a2020q1-exhibit31410qa.htm EX-31.4 6947
  Complete submission text file 0001628280-20-010607.txt   309320

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20200331.xsd EX-101.SCH 2460
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20200331_cal.xml EX-101.CAL 738
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20200331_def.xml EX-101.DEF 1675
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20200331_lab.xml EX-101.LAB 32991
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20200331_pre.xml EX-101.PRE 17534
9 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20200331_htm.xml XML 18318
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-33637 | Film No.: 201047597
SIC: 2834 Pharmaceutical Preparations